Tantti Laboratory Inc. was founded in 2014 by eight distinguished professors in Taiwan with expertise in Chemical and Materials Engineering. Since its inception, the company has developed two platform technologies which use Microfluidics and In-mold polymerization to create highly ordered micro- and nano-porous biomaterials. Our technologies have been patented around the world (e.g. USA, Europe, Japan, Taiwan and China) and offer great flexibilities in biomaterials (e.g. collagen or animal-free), scaffold thickness, pore sizes, mechanical stiffness adjustments, and biodegradability, adapting to versatile cell expansion and bioseparation applications.
Tantti Laboratory Inc. has developed Tantti® BioScaffolds platform technology to create highly ordered micro-porous 3D BioScaffold and UniTantrix™ Microcarrier, which can be prepared with a variety of biological materials (such as collagen or animal-free materials). In order to solve the bottleneck of high-density cell production in biomedical industry, the porous structure of 3D BioScaffold and UniTantrix™ Microcarrier can provide more surface area for cell attachment and proliferation. In addition, it can be dissolved to completely recover the cells. Physical attributes of these BioScaffolds, including thickness, pore size, and mechanical strength (stiffness) can be customized per the request of users. 3D BioScaffold and UniTantrix™ Microcarrier have been used in cells production, vaccine/viral particle production, cell therapy, tissue engineering, regenerative medicine, and high-throughput/content drug screening. Recently, we have collaborated with world-leading distributors and online platforms to promote the 3D Bioscaffold and UniTantrix™ Microcarriers, and have also cooperated with well-known research institutions, vaccine manufacturers, and cell therapy companies around the world for development of customized BioScaffold.
In addition, Tantti® has created a fourth-generation monolithic column (Tantti® Monolith) which overcomes high-throughput downstream purification issues of biological products in current monolithic columns (e.g. high throughput, reproducibility, etc.) The unique honeycomb nano-porous structure of Tantti® Monolith not only has the advantages of low backpressure and high flow rate, but also is easy to scale-up. In addition, Tantti® Monolith can enhance downstream purification efficiency of biological products, such as proteins, antibodies, exosomes, and viral vectors (Lentivirus, Adeno, adeno associated virus etc.), which can lower the costs of protein drugs, vaccines and gene therapy application. Exciting performance has been observed in purification of influenza virus (H7N9), enterovirus (EV71), lentivirus, adenovirus and AAVs (Adeno-associated viruses). Currently, Tantti® Monolith is cooperating with global chromatography manufacturers in Japan, especially for the viral vector purification for gene and CAR-T cell therapy. Additionally, Tantti Laboratory Inc. has signed a memorandum of partnership with China's major chromatography column producer and starts rolling out monolith products to the Greater China market.
We believe Tantti’s innovative biomaterial technologies not only provide cost-effective solutions to our customers but also reward profitable values for our employees and shareholders. Our commitments to innovation and quality products drive our long-term sustainable growth together with our partners. We strive to become a world-class, global biomaterial company and sincerely welcome you to collaborate with us. Through our partnership, we can build a healthier and more beautiful future for tomorrow.
Time Line Company History
Signed industry-academy cooperative research project contract with National Central University
Signed industry-academy cooperative research project contract with National Chiao Tung University
Received grants from TIEC